| ‘Real-life’information on pulmonary arterial hypertension: the iPHnet Project R Poscia, S Ghio, M D’Alto, P Vitulo, M Mule, C Albera, F Parisi, ... Current Medical Research and Opinion 30 (12), 2409-2414, 2014 | 14 | 2014 |
| 180 Long term aztreonam solution for inhalation in adult cystic fibrosis (CF) patients with severe lung disease B Messore, C Bena, C Biglia, S Demichelis, C Ferrero, E Rizza, ... Journal of Cystic Fibrosis 1 (16), S113, 2017 | | 2017 |
| 6 Minute Walk Distance (6MWD) And Forced Vital Capacity (FVC) In Patients With Idiopathic Pulmonary Fibrosis (IPF): Similar Pattern Of Pirfenidone Response D Valeyre, C Albera, RM Du Bois, WZ Bradford, U Costabel, TE King, Jr, ... D48. INTERSTITIAL LUNG DISEASE: PATHOBIOLOGY, BIOMARKERS AND TREATMENT …, 2010 | 1 | 2010 |
| 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis RM du Bois, C Albera, WZ Bradford, U Costabel, JA Leff, PW Noble, ... European Respiratory Journal 43 (5), 1421-1429, 2014 | 226 | 2014 |
| 6-minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis (IPF): confirmation of test performance characteristics SD Nathan, RM Du Bois, C Albera, WZ Bradford, U Costabel, A Kartashov, ... B17. CLINICAL TRIALS IN IDIOPATHIC PULMONARY FIBROSIS: RETHINKING ENDPOINTS …, 2013 | 3 | 2013 |
| 6-minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis (IPF): Confirmation of the minimal clinically important difference (MCID) S Nathan, C Albera, R du Bois, W Bradford, U Costabel, T King, P Noble, ... European Respiratory Journal 40 (Suppl 56), 2012 | | 2012 |
| 6-minute walk test distance (6MWD) is a reliable, valid, and responsive outcome measure that predicts mortality in patients with IPF RM Du Bois, C Albera, U Costabel, WZ Bradford, A Kartashov, PW Noble, ... A23. IDIOPATHIC PULMONARY FIBROSIS: EPIDEMIOLOGY, BIOMARKERS, AND OUTCOMES …, 2010 | 10 | 2010 |
| A european pooled analysis of epidemiological registries in idiopathic pulmonary fibrosis (IPF): demographics and baseline characteristics W Wuyts, V Poletti, C Albera, A Guenther, E Bendstrup, J Bruhwyler, ... American Journal Of Respiratory And Critical Care Medicine 191, 2015 | 1 | 2015 |
| A novel clinical prediction model for near-term mortality in patients with idiopathic pulmonary fibrosis (IPF) RM Du Bois, C Albera, WZ Bradford, U Costabel, PW Noble, SA Sahn, ... B17. CLINICAL TRIALS IN IDIOPATHIC PULMONARY FIBROSIS: RETHINKING ENDPOINTS …, 2013 | 5 | 2013 |
| A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis J Behr, E Bendstrup, B Crestani, A Günther, H Olschewski, M Skoeld, ... European Respiratory Journal 44 (Suppl 58), 2014 | | 2014 |
| A15 THE LONG AND WINDING ROAD TO IPF TREATMENT: EXPANDED ANALYSES OF PIRFENIDONE AND NINTEDANIB: Effect Of Continued Treatment With Pirfenidone Following A Clinically … SD Nathan, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ... American Journal of Respiratory and Critical Care Medicine 191, 1, 2015 | | 2015 |
| A15 THE LONG AND WINDING ROAD TO IPF TREATMENT: EXPANDED ANALYSES OF PIRFENIDONE AND NINTEDANIB: Pirfenidone Is Efficacious In Patients With Idiopathic Pulmonary Fibrosis (ipf … C Albera, WZ Bradford, U Costabel, EA Fagan, I Glaspole, MK Glassberg, ... American Journal of Respiratory and Critical Care Medicine 191, 1, 2015 | | 2015 |
| A15 THE LONG AND WINDING ROAD TO IPF TREATMENT: EXPANDED ANALYSES OF PIRFENIDONE AND NINTEDANIB: Safety Of Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis (ipf … L Lancaster, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ... American Journal of Respiratory and Critical Care Medicine 191, 1, 2015 | | 2015 |
| A26 EVERY LITTLE THING: CONNECTIVE-TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASE: Safety And Tolerability Of Pirfenidone In Patients With Systemic Sclerosis-Associated … D Khanna, C Albera, A Fischer, N Khalidi, G Raghu, L Chung, D Chen, ... American Journal of Respiratory and Critical Care Medicine 191, 1, 2015 | | 2015 |
| A38 DIAMONDS ARE FOREVER BUT NEW TREATMENTS FOR INTERSTITIAL LUNG DISEASE CAN'T WAIT: Analysis Of Pooled Data From 3 Phase 3, Multinational, Randomized, Double-Blind, Placebo … PW Noble, C Albera, WZ Bradford, U Costabel, RM du Bois, EA Fagan, ... American Journal of Respiratory and Critical Care Medicine 189, 1, 2014 | | 2014 |
| A38 DIAMONDS ARE FOREVER BUT NEW TREATMENTS FOR INTERSTITIAL LUNG DISEASE CAN'T WAIT: Effect Of Treatment With Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis (ipf … DJ Lederer, C Albera, WZ Bradford, U Costabel, RM du Bois, EA Fagan, ... American Journal of Respiratory and Critical Care Medicine 189, 1, 2014 | | 2014 |
| Activated and memory alveolar T-lymphocytes in idiopathic eosinophilic pneumonia C Albera, P Ghio, P Solidoro, I Mabritto, L Marchetti, E Pozzi European Respiratory Journal 8 (8), 1281-1285, 1995 | 25 | 1995 |
| Adenosine deaminase activity and fibronectin levels in bronchoalveolar lavage fluid in sarcoidosis and tuberculosis. C Albera, I Mabritto, P Ghio, P Solidoro, L Marchetti, E Pozzi Sarcoidosis 10 (1), 18-25, 1993 | 23 | 1993 |
| Akkermans R. 47th Union World Conference on Lung Health. Lancet Respir Med 2017; 5: 14–15—In the final paragraph of this News piece, the quote from Arnaud Trébucq should have … SD Nathan, C Albera, WZ Bradford | | 2016 |
| Aktuelle Aspekte der Lungentransplantation P von Samson-Himmelstjerna Zentralblatt für Chirurgie-Zeitschrift für Allgemeine, Viszeral-, Thorax-und …, 2018 | | 2018 |
